In connection with the conduct of a special military operation, attention to the problems of providing medical services to the population has been completely reduced. At the same time, only in the last week of September 2023, more than 23 million cases of coronavirus infection were detected by citizens of our country, which indicates the relevance of this issue. At the same time, the authors pose the problem of maintaining a balance of interests of the rightholders of medicines, medical products, as well as the end user. By applying comparative legal analysis, the authors come to the conclusion about the need for regulatory legal consolidation of granting preferences to organizations that actively apply in practice the results of intellectual activity in the field of production of medicines.
|
